Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lupron Depot is a prescription gonadotropin-releasing hormone agonist containing leuprolide acetate in long-acting injectable formulations. Current 7.5 mg, 22.5 mg, 30 mg, and 45 mg products treat advanced prostate cancer. Separate 3.75 mg and 11.25 mg products treat endometriosis and are used with iron therapy for selected patients with fibroid-related anemia before surgery.
read more about lupron depot ...Leuprolide initially stimulates pituitary release of luteinizing hormone and follicle-stimulating hormone. With continued treatment, pituitary gonadotropin secretion decreases, suppressing testosterone production in men and estrogen production in women. The initial hormone increase can temporarily worsen symptoms before suppression occurs.
The prostate cancer formulations are used in adults with advanced prostate cancer. The gynecologic formulations treat endometriosis and are used with iron therapy to improve anemia associated with uterine fibroids before surgery. Lupron Depot-PED is a separate product for children with central precocious puberty and has different dosing instructions.
For advanced prostate cancer, the intramuscular schedules are 7.5 mg every four weeks, 22.5 mg every 12 weeks, 30 mg every 16 weeks, or 45 mg every 24 weeks. Gynecologic formulations use 3.75 mg monthly or 11.25 mg every three months. Endometriosis treatment is limited to six months initially, with up to 12 months total when appropriate norethindrone acetate add-back therapy is included. The formulations are not interchangeable.
Serious concerns include initial tumor flare, urinary obstruction, spinal cord compression, metabolic changes, cardiovascular events, QT prolongation, seizures, severe skin reactions, and fetal harm. Gynecologic treatment can reduce bone mineral density, particularly without add-back therapy. Testosterone, prostate-specific antigen, metabolic measurements, and other assessments are monitored according to the indication.
Different formulations treat advanced prostate cancer, endometriosis, and selected cases of fibroid-related anemia before surgery.
The available regimens use an intramuscular injection every four, 12, 16, or 24 weeks, depending on the formulation.
Gynecologic products use 3.75 mg monthly or 11.25 mg every three months under indication-specific limits.
No. Different depot formulations have distinct release characteristics and are not directly interchangeable.
DailyMed - LUPRON DEPOT (leuprolide acetate) kit. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd. Date Accessed October 13, 2026.
Leuprolide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548676/. Date Accessed October 13, 2026.
Leuprolide. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551662/. Date Accessed October 13, 2026.
Leuprolide Acetate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Leuprolide-Acetate. Date Accessed October 13, 2026.
Leuprolide Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a685040.html. Date Accessed October 13, 2026.